Zevra Therapeutics, Inc. (1GDA.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:04AM CEST. Market open.
| Previous close | 4.7200 |
| Open | 4.6200 |
| Bid | 4.6000 x N/A |
| Ask | 4.7200 x N/A |
| Day's range | 4.6200 - 4.6200 |
| 52-week range | 3.8200 - 6.4500 |
| Volume | |
| Avg. volume | 18 |
| Market cap | 193.349M |
| Beta (5Y monthly) | 1.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript May 8, 2024 Zevra Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics’ First Quarter 2024 Corporate Update and Financial […]
- Simply Wall St.
Zevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zevra Therapeutics ( NASDAQ:ZVRA ) First Quarter 2024 Results Key Financial Results Revenue: US$3.43m (up 19% from 1Q...
- GuruFocus.com
Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Despite a net loss, Zevra Therapeutics advances with promising drug trials and secures substantial financial flexibility through a new credit facility.
© 2024 Yahoo. All rights reserved.